The abortion rate is holding steady in the US despite total and partial bans in some states – largely because of travel across state lines and a significant increase in telehealth appointments, a new report says.
US regulatory officials are weighing changes to the ways mifepristone, an abortion medication, may be dispensed, but they have reportedly pushed their review until after the midterm elections, given the widespread support for abortion across the US.
The number of abortions in the US increased slightly last year, from 1.124m to 1.126m, according to a Guttmacher Institute report. There’s also a shift away from traveling and toward telehealth, in which providers may prescribe mail-order pills.
One major change in this report is the provision of telehealth for patients in states with total bans – with clinicians in states such as New York or Massachusetts, which have shield laws to protect providers, seeing and prescribing remotely to patients living in states such as Texas or Alabama.
Health Glance
More than 100 substances widely used in common US foods, supplements and beverages underwent no health and safety review by the US Food and Drug Administration, a new analysis of federal records finds.
Since September, 16 major drug companies have inked deals with the Trump administration to lower prices. But in January — the time of year when pharmaceutical companies typically roll out price hikes — all 16 companies released higher list prices for some of their drugs.





























